Maze Therapeutics Inc (MAZE)

NASD · Healthcare · Biotechnology · USA

Maze Therapeutics Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.

Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases. The company uses its Compass platform to identify genetic variants and understand their role in disease. It is advancing two clinical programs: MZE829, an oral inhibitor for APOL1-mediated kidney disease, and MZE782, an oral inhibitor for phenylketonuria and chronic kidney disease.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Maze Therapeutics Inc stock.

Our verdict on MAZE

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover two fiscal years and projecting growth needs four in a row.

ETFs with the most weight in MAZE

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than MAZE in Biotechnology

129 more in this industry show a wider margin of safety.

Is MAZE undervalued or overvalued?

We do not publish a verdict on MAZE yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of MAZE?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.